Article Details - Overview
This activity is part of PER's Integrated Oncology Learning Series:
A Focus on Thoracic Malignancies
New Developments in Maintenance Therapy and Novel Targeted Agents for Advanced Non–Small-Cell Lung Cancer
1 AMA PRA Category 1 Credit(s)™
Release Date: September 30, 2009
Expiration Date: September 30, 2010
Upon completion of this educational activity, you should be able to:
- Summarize clinical data on antifolate maintenance therapy for patients with advanced NSCLC
- Evaluate the efficacy of maintenance therapy with an EGFR TKI in advanced NSCLC
- Describe clinical data on maintenance therapy with an anti-VEGF MoAb plus an EGFR TKI in advanced NSCLC
- Assess clinical outcomes with an EGFR TKI as first-line treatment of advanced NSCLC by EGFR mutation subtype
- Evaluate the efficacy of an ALK/c-Met TKI in the treatment of advanced NSCLC harboring ALK fusion genes
- Discuss the efficacy of an irreversible EGFR/HER2 TKI in the treatment of advanced NSCLC harboring EGFR mutations
Choose a Participation Option
To claim credit for this activity you must:
- Take the Pretest
- Participate in the Activity
- Take the Posttest
- Take the Evaluation
- Claim your Credit Amount & Certificate Type
If you do not wish to claim credit:
You may bypass all CE information, tests and evaluations and go straight to the activity.
You may not request credit after viewing the activity.
I wish to participate in this
activity and claim credit.
I wish to view the activity
without claiming credit.